The impact of PEGylation on biological therapies

BioDrugs

Volumn 22, Issue 5, 2008, Pages 315-329

  Veronese, Francesco M ^a   Mero, Anna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antibody optimisation technologies; Certolizumab pegol, general; PEG haemoglobin, general; Pegademase, general; Pegaptanib, general; Pegaspargase, general; Pegfilgrastim, general; Peginterferon alfa, general; Pegvisomant, general; Research and development

Indexed keywords

ARGININE; ASPARAGINASE MACROGOL; CARBOXYLIC ACID; CERTOLIZUMAB PEGOL; CYSTEINE; ERYTHROPOIETIN; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HISTIDINE; HYDROXYL GROUP; IMIDAZOLE; INTERFERON; MACROGOL; MIRCERA; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PEGYLATED URICASE; POLYMER; PURICASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; URATE OXIDASE;

ACROMEGALY; ACYLATION; AMINO ACID SEQUENCE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; MEDICAL RESEARCH; PEGYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; TREATMENT INDICATION; VIRUS INFECTION;

ANIMALS; CYTOKINES; HUMANS; PEPTIDES; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 51549092094     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822050-00004     Document Type: Review

References (103)

1. Maeda H. SMANCS and polymer conjugated macromolecular drugs: advances in cancer therapeutics. Adv Drug Del Rev 1991; 6: 181-202
2. Torchilin VP. Immobilised enzymes as drugs. Adv Drug Del Rev 1987; 1: 41-86
3. Abuchowski A, Van E, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252: 3578-81
4. Israelachvili J. The different faces of poly(ethylene glycol). Proc Natl Acad Sci U S A 1997; 94: 8378-9
5. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21
6. Kinstler OB, Brems DN, Lauren SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 1996; 13: 996-1002
7. Veronese FM, Saccà B, Polverino de Laureto P, et al. New PEGs for peptide and protein modification, suitable for identification of the PEGylation site. Bioconjug Chem 2001; 12: 62-70
8. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001; 22: 405-17
9. Sato H, Ikea M, Suzuki K, et al. Site-specific modification of interleukin-2 by the combined use of genetic engineering techniques and transglutaminase. Biochemistry 1996; 35: 13072-80
10. Balan S, Choi JW, Godwin A, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem 2007; 18: 61-76
11. Zhao H, Yang K, Martinez A, et al. Linear and branched bicine linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. Bioconjug Chem 2006; 17: 341-51
12. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Del Rev 2002; 54: 459-76
13. Levy Y, Hershfield MS, Fernandez-Mejia C, et al. Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with poly(ethylene glycol) modified adenosine deaminase. J Pediatr 1988; 113: 312-7
14. Graham LM. Pegasparaginase: a review of clinical studies. Adv Drug Del Rev 2003; 10: 1293-302
15. Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004; 18: 1072-7
16. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547-70
17. Monkarsh SP, Ma Y, Aglione A, et al. Positional isomers of mono-pegylated interferon α-2a: isolation, characterization, and biological activity. Anal Biochem 1997; 247: 434-40
18. Roelfsema F, Biermasz NR, Pereira AM, et al. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine 2006; 1: 385-98
19. Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Prog Polym Sci 2007; 32: 933-61
20. Blick S, Curran M. Certolizumab pegol. Biodrugs 2007; 21: 196-201
21. Inada Y, Takahashi K, Yoshimoto T, et al. Application of PEG-enzyme and magnetite-PEG-enzyme conjugates for biotechnological processes. Trends Biotechnol 1988; 6: 131-4
22. Harris JM. Polyethylene glycol chemistry, biochemical and biochemical applications. New York: Plenum Press, 1992
23. Harris JM, Zalipsky S, editors. Polyethylene glycol, chemistry and biological applications. Washington, DC: American Chemical Society, 1997
24. Veronese FM, Harris JM. Peptide and protein PEGylation III: advances in chemistry and clinical applications. Adv Drug Deliv Rev 2008; 60 (1): 1-2
25. Greenwald RB. PEG drugs: an overview. J Control Release 2001; 74: 159-71
26. Pasut G, Guiotto A, Veronese FM. Protein, peptide and non-peptide drug PEGylation for therapeutic application. Exp Opin Ther Pat 2004; 14: 859-94
27. 2 derivative. J Inorg Biochem 1990; 39: 149-59
28. Greenwald RB, Choe YH, McGuire J, et al. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003; 55: 217-50
29. Harris JM, Sedaghat-Herati MR. Preparation and use of polyethylene glycol propionaldehyde [US patent 5252714; online]. Available from URL: http://patft.uspto.gov/netahtml/PTO/srchnum.htm [Accessed 2008 Aug 26]
30. Takakura Y, Fujita T, Hashida M, et al. Disposition of macromolecules in tumor bearing mice. Pharm Res 1990; 7: 339-46
31. Sartore L, Caliceti P, Schiavon O, et al. Accurate evaluation method of the polymer content in monomethoxy(polyethylene glycol) modified proteins based on amino acid analysis. Applied Biochem Biotechnol 1991; 31: 213-22
32. Miron T, Wilchek M. A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins. Bioconjug Chem 1993; 4: 568-9
33. Veronese FM, Largajolli R, Boccu E, et al. Activation of monomethoxy(polyethylene glycol) by phenylchloroformiate and modification of ribonuclease and consuperoxide dismutase. Appl Biochem Biotechnol 1985; 11: 141-52
34. Lee S, McNemar C. Substantially pure histidine-linked protein polymer conjugates [US patent 5985263; online]. Available from URL: http://patft.uspto. gov/netahtml/PTO/srchnum.htm [Accessed 2008 Aug 26]
35. Morpurgo M, Veronese FM, Kachensky D, et al. Preparation and characterization of polyethylene glycol vinyl sulfone. Bioconjug Chem 1996; 7: 2417-24
36. Woghiren C, Sharma B, Stein S. Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification. Bioconjug Chem 1993; 4: 314-8
37. Veronese FM, Mero A, Caboi F, et al. Site-specific PEGylation of G-CSF by reversible denaturation. Bioconjug Chem 2007; 18: 1824-30
38. Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonist: discovery, development, and use in patients with acromegaly. Endocr Rev 2002; 23: 623-46
39. Zalipsky S, Meno-Rudolph S. Hydrazide derivatives of polyethylene glycol and their bioconjugates, in polyethylene glycol chemistry and biological applications. In: Harris JM, Zalipsky S, editors. ACS Symposium Series 1997; 680: 318-41
40. Tayar E, Zhao X, Bentley MD. PEG-LHRH analog conjugates [world patent publication no. WO/1999/055376; online]. Available from URL: http://www.wipo.int/pctdb/en/ [Accessed 2008 Aug 26]
41. Orsatti L, Veronese FM. An unusual coupling of poly(ethylene glycol) to tyrosine residues in epidermal growth factor. J Bioac Comp Polymer 1999; 14: 429-36
42. DeFrees S, Wang ZG, Xing R, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 2006; 16: 833-43
43. Gaertner HF, Puigserver AJ. Increased activity and stability of poly(ethylene glycol)-modified trypsin. Enzyme Microb Technol 1992; 14: 150-5
44. Fontana A, Spolaore B, Mero A, et al. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Del Rev 2008; 60: 13-28
45. Messersmith PB, Hu B-H, Ritter Jones M. Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation [US patent 7208171; online]. Available from URL: http://patft.uspto.gov/netahtml/ PTO/srchnum.htm [Accessed 2008 Aug 26]
46. Monfardini C, Schiavon O, Caliceti P, et al. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995; 6: 62-9
47. Veronese FM, Caliceti P, Schiavon O. Branched and linear poly(ethylene glycol): influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Comp Polym 1997; 12: 196-207
48. Srividhya M, Preethi S, Gnanamani A, et al. Sustained release of protein from polyethylene glycol incorporated amphiphilic comb like polymers. Int J Pharm 2006; 326: 119-27
49. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001; 12: 195-202
50. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249-304
51. Caliceti P, Schiavon O, Veronese FM. Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug Chem 2001; 12: 515-22
52. Morpurgo M, Veronese FM. Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol 2004; 283: 45-70
53. Federico R, Cona A, Caliceti P, et al. Histaminase PEGylation: preparation and characterization of a new bioconjugate for therapeutic application. J Control Release 2006; 115: 168-74
54. Visentin R, Pasut G, Veronese FM, et al. Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N-(3- diphenylphosphinopropionyl)glycil] cysteine ligand with poly(ethylene glycol). Bioconjug Chem 2004; 15: 1046-54
55. Pradhananga S, Wilkinson I, Ross RJ. Pegvisomant: structure and function. J Mol Endocrinol 2002; 29: 11-4
56. Bell EA, Wall GC. Pediatric constipation therapy using guidelines and polyethylene glycol 3350. Ann Pharmacother 2004; 38: 686-93
57. Pashankar DS, Loening-Baucke V, Bishop WP. Polyethylene glycol 3350 without electrolytes: a new safe, effective, and palatable bowel preparation for colonoscopy in children. J Pediatr 2004; 144: 358-62
58. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice. J Pharm Sci 1994; 83: 601-6
59. Kawai F. Microbial degradations of polyethers. Appl Microbiol Biotechnol 2002; 58: 30-8
60. Beranova M, Wasserbauer R, Vancurova D, et al. Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. Biomaterials 1990; 11: 521-4
61. Working PK, Newman MS, Johnson J, et al. Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives. In: Harris JM, Zalipsky S, editors. Polyethylene glycol chemistry and biological applications. ACS Symposium Series 1997; 680: 45-57
62. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1: 297-315
63. Bendele A, Seely J, Richey C, et al. Short communication: renal tubular vacuolation in animals treated with poly(ethylene glycol)-conjugated proteins. Toxicol Sci 1999; 42: 152-7
64. Webster R, Didier E, Harris P, et al. Pegylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metabol Dis 2007; 35: 9-16
65. Fibbe WE, Daha MR, Hiemstra PS, et al. Interleukin-1 and poly(rI)-poly(rC) induce production of granulocyte CSF, macrophage CSF and granulocyte-macrophage CSF by human endothelial cells. Exp Hematol 1989; 17: 229-34
66. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 1985; 82: 1526-30
67. Lu HS, Clogston CL, Narhi LO, et al. Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli: characterization of the disulfide-reduced intermediates and cysteine-serine analogs. J Biol Chem 1992; 267: 8770-7
68. Kinstler O, Molineaux G, Treuheit M, et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002; 54: 477-86
69. Molineaux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004; 10: 1235-44
70. Piedmonte DM, Treuheit MJ. Formulation of Neulasta® (pegfilgrastim). Adv Drug Del Rev 2008; 60: 50-8
71. Luxon BA, Grace M, Brassard D, et al. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002; 24: 1363-83
72. Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-30
73. Hinds KD, Kim SW. Effect of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002; 54: 505-30
74. Hershfield MS, Chaffee S, Koro-Johnson L, et al. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Pro Natl Acad Sci U S A 1991; 88: 7185-9
75. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci Epub 2008 Jan 15
76. Parkinson C, Scarlett JA, Trainer PJ. Pegvisomant in the treatment of acromegaly. Adv Drug Deliv Rev 2003; 55: 1303-14
77. Ng EWM, Shima DT, Calias P, et al. A targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Dis 2006; 5: 123-32
78. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Del Rev 2002; 54: 531-45
79. Chapman AP, Antoniw P, Spitali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17: 780-3
80. Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008; 7: 641-2
81. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. PRECISE 1 Study Investigators. N Engl J Med 2007; 357: 228-38
82. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. PRECISE 2 Study Investigators. N Engl J Med 2007; 357: 239-50
83. Fleischmann R, Mason D, Cohen S. Efficacy and safety of certolizumab pegol monotherapy in patients with rheumatoid arthritis failing previous DMARD therapy [abstract]. Ann Rheum Dis 2007; 66 Suppl. II: 169
84. Smolen J, Brzezicki J, Mason D, et al. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study [abstract]. Ann Rheum Dis 2007; 66 Suppl. II: 187
85. Reich K, Tasset C, Ortonne J. Efficacy and safety of certolizumab pegol in patients with chronic plaque psoriasis: preliminary results of a randomised, double-blind, placebo-controlled trial [abstract]. Ann Rheum Dis 2007; 66 Suppl. II: 251
86. Edwards C. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999; 58: I73-81
87. Paz K, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2: current status and future perspective. Front Biosci 2005; 10: 1415-39
88. Nishimura H, Ashihara Y, Matsushima A, et al. Modification of yeast uricase with poly(ethylene glycol): disappearance of binding ability towards anti-uricase serum. Enzyme 1979; 24: 261-4
89. Abuchowski A, Karp D, Davis FF. Reduction of plasma urate levels in the cockerel with poly(ethylene glycol)-uricase. J Pharmacol Exp Ther 1981; 219: 352-4
90. Caliceti P, Morpurgo M, Schiavon O, et al. Preservation of thrombolytic activity of urokinase modified with monomethoxypoly(ethylene glycol). J Bioact Comp Polym 1999; 4: 252-66
91. Chua CC, Greenberg ML, Viau AT, et al. Use of poly(ethylene glycol)-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988; 109: 114-7
92. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003; 21: 4402-6
93. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Del Rev 2008; 60: 59-68
94. Sundy JS, Ganson NJ, Kelly SJ, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007; 56: 1021-8
95. Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006; 8 (1): R12
96. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983; 74: 124-31
97. Fisher TC, Armstrong JK, Wenby RW, et al. Isolation and identification of a human antibody to poly(ethylene glycol) [abstract]. Blood 2003; 102: 559
98. Hess JR, Macdonald VM, Brinkley WW. Systemic and pulmonary hypertension after resuscitation with cell free hemoglobin. J Appl Physiol 1993; 74: 1769-78
99. Nho K, Zalipsky S, Davis F. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute [US patent 5386014; online]. Available from URL: http://patft.uspto.gov/netahtml/PTO/srchnum.htm [Accessed 2008 Aug 26]
100. β: correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem 2003; 14: 464-72
101. Hu T, Prabhakaran M, Acharya S, et al. Influence of the chemistry of conjugation of polyethylene glycol to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem J 2005; 392: 555-64
102. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60
103. Zhao H, Rubio B, Sapra P, et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 2008; 19: 849-59